Answers are grounded in this paper and cite their sources.
It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated to reduce risk of hospitalization/death by 79%. This study assessed the impact of amubarvimab/romlusevimab on late outcomes, including Long COVID.
No takes yet. Share an insight, caveat, or question.
Evering et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: